Auna (AUNA) Q3 2026 Earnings Call Transcript
Auna (AUNA) reported Q3 2026 earnings, highlighting 10% top-line growth on an FX-neutral basis. Mexico saw accelerated growth and profitability, while Colombia faced medical cost pressures. Peru's revenue grew, but profitability declined due to penalties. The company maintained strong cash generation, reducing leverage to 3.5x. Auna remains confident in its long-term growth potential.
How this was made

The 30-second read
Why it matters
The transcript discloses segment-level profitability pressures (Colombia oncology contract adverse costs and regulatory price caps) alongside improving cash conversion and leverage progress, which can drive near-term valuation debate around margin durability versus growth.
Market read
Traders can reassess near-term margin risk in Colombia versus strength in Mexico and Peru, using the call’s explicit drivers (contract termination, price caps, penalties, and volume/utilization metrics).
What to watch
Mexico’s VAT deductibility headwinds are described as offset by network volume growth, so the consolidated story may be more resilient than segment EBITDA implies if utilization trends persist.
Background
The article is a transcript of Auna’s Q3 2026 earnings call, covering regional performance (Mexico, Peru, Colombia), cash generation, leverage, and specific contract and regulatory drivers.
Ticker impact
Auna reports Q3 growth and cash generation, but flags Colombia oncology contract losses and regulatory price caps pressuring segment EBITDA.
Likely downside bias as investors focus on Colombia margin pressure and the terminated risk-sharing contract, despite solid consolidated revenue and free cash flow.
The call provides specific drivers for segment EBITDA declines (about 4% of Colombia revenue adverse costs, contract termination, and ongoing price-cap impact) alongside stronger Mexico and Peru metrics, implying mixed but net risk to margins.
Market effects
Highlights how oncology risk-sharing contract economics and regulatory price caps can quickly swing profitability for integrated healthcare providers.
Colombia is the key swing factor due to contract-driven adverse medical costs and mid-August price caps.
Limited direct global read-through, but reinforces investor sensitivity to healthcare reimbursement regulation and contract risk management.
Counterpoint
Termination of the problematic Colombia oncology risk-sharing contract and active legal recovery efforts could reduce future downside more than the current quarter suggests.
Key entities
- companyAuna
Integrated healthcare provider reporting Q3 2026 results and discussing segment profitability drivers in Mexico, Peru, and Colombia.
- business_unitIMAT Oncomédica
Colombia facility where Auna expanded ICU and hospitalization capacity to support high-complexity demand.
- business_unitOncosalud
Peru oncology platform referenced for oncology MLR and plan membership growth.

